香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （前稱BeiGene, Ltd. 百濟神州有限公司） （先前於開曼群島註冊成立的有限公司，並已在瑞士存續註冊） （股份代號：06160） 變更英文公司名稱及英文股份簡稱 茲提述BeOne Medicines Ltd.百濟神州有限公司（「本公司」）日期為2025年5月27日 的公告，內容有關（其中包括）完成遷址及存續及公司英文名稱變更（「該公告」）。 本公司欣然宣佈，香港公司註冊處處長已於2025年10月2日發出註冊非香港公司 變更名稱註冊證明書，證明BeOne Medicines Ltd.已根據香港法例第622章《公司 條例》第16部在香港註冊為本公司英文名稱。 變更英文股份簡稱 公司英文名稱變更完成後，於香港聯交所進行股份交易的英文股份簡稱將由 「BEIGENE」變更為「BEONE MEDICINES」，自2025年10月22日星期三上午九時 ...

Core Viewpoint - The article emphasizes the significant role of A-share listed companies in driving China's high-quality economic development through innovation, with substantial R&D investments and transformative achievements in various sectors [1][2]. Group 1: Innovation and R&D Investment - A-share listed companies have contributed over 1.88 trillion yuan in R&D, accounting for 51.96% of the national R&D expenditure, with a 48% increase in overall R&D investment since 2020 [2]. - The R&D intensity of A-share companies has risen to 2.61%, surpassing the average of EU countries, with notable contributions from companies like BYD and CATL [2]. - The emergence of innovative drugs, such as Zepzelca, showcases the global competitiveness of Chinese original research drugs, supported by significant R&D investments from companies like BeiGene [2][3]. Group 2: Technology and Industry Integration - Listed companies are pivotal in transforming scientific achievements into industrial applications, exemplified by advancements in tire technology and battery recycling [3]. - The integration of AI and digital technologies in manufacturing has led to significant efficiency improvements, with smart factories achieving notable reductions in production cycles and defect rates [5][6]. Group 3: High-end, Intelligent, and Green Transformation - Companies are focusing on high-end manufacturing to enhance brand value, as seen with LONGi Green Energy's advancements in solar technology [5]. - The shift towards intelligent manufacturing is evident, with significant investments in digital transformation across various industries, including agriculture and logistics [6][7]. - The green transformation is highlighted by the establishment of a comprehensive renewable energy industry chain, with A-share companies investing 1.3 trillion yuan in renewable projects [7]. Group 4: Global Expansion and Collaboration - A-share companies have significantly increased their overseas revenue, reaching 9.52 trillion yuan, marking a 56.58% growth since 2020 [8]. - The export of innovative products, particularly in pharmaceuticals, has seen substantial growth, indicating a shift towards higher value-added exports [9]. - Companies are adopting a collaborative approach in global markets, integrating local manufacturing and supply chain partnerships to enhance their international presence [10].

Core Insights - A-share listed companies have significantly contributed to China's high-quality economic development, with over 1.8 trillion yuan in R&D investment and a market capitalization exceeding 100 trillion yuan [1] - The past five years have seen a transition from quantity expansion to quality improvement among listed companies, marking a critical leap in their development [1][2] R&D Investment - In 2024, China's total R&D investment is expected to exceed 3.6 trillion yuan, a 48% increase from 2020, with listed companies contributing 1.88 trillion yuan, accounting for 51.96% of the national total [3] - The R&D intensity of listed companies has risen to 2.61%, up by 0.1 percentage points from the previous year, with 26 companies entering the "billion R&D club" [3] Innovation and Technology - Major technological achievements during the "14th Five-Year Plan" include advancements in space exploration, high-speed rail, and renewable energy, with listed companies playing a pivotal role in these innovations [2] - Companies like BeiGene have invested heavily in R&D, with over 47 billion yuan from 2021 to 2024, showcasing the potential of Chinese original research drugs on the global stage [3] Industry Transformation - Listed companies are integrating technological innovation with industrial innovation, exemplified by successful case studies in tire manufacturing and battery recycling [4] - The shift towards smart manufacturing has led to significant efficiency improvements, with over 230 exemplary smart factories reporting an average production efficiency increase of 22.3% [6][7] Green Development - The "14th Five-Year Plan" has seen the establishment of the world's largest renewable energy industry chain, with listed companies investing 1.3 trillion yuan in renewable projects [8] - Companies like Yanjing Beer are implementing green practices throughout their production lifecycle, contributing to a 16.9% reduction in carbon emissions per unit of revenue since 2020 [9] Global Expansion - A-share listed companies achieved 9.52 trillion yuan in overseas revenue in 2024, a 56.58% increase from 2020, indicating a qualitative shift in their global presence [10] - The export of innovative drugs has surged, with nearly 66 billion USD in foreign licensing agreements in the first half of 2025, reflecting the global recognition of China's R&D capabilities [10] Conclusion - The trajectory of A-share listed companies reflects the microcosm of China's economic high-quality development, transitioning from innovation-driven breakthroughs to global value elevation [11]

Core Insights - The 2025 Sustainable Global Leaders Conference is being held in Shanghai from October 16 to 18, highlighting the importance of sustainable development and innovation in the financial sector [1] - Guo Chuan Zhou, Chairman of Yuekai Securities, emphasized the need for "patient capital" to support transformation and long-term development in technology finance [2] Company Focus - Yuekai Securities is strategically positioned in the Guangzhou Economic and Technological Development Zone, a key area in the Guangdong-Hong Kong-Macao Greater Bay Area known for its economic scale and technological innovation [2] - The company is focusing on three main levels of service in technology finance, with "transformation" being the primary task [2] Investment Strategy - The core approach of Yuekai Securities in serving the technology industry is "investment-led," aiming to drive growth through strategic investments [2] - The investment segment has been concentrating on "high-end" fields, with notable projects including investments in leading biopharmaceutical companies listed on the Sci-Tech Innovation Board [2]

专题：2025可持续全球领导者大会&首届绿色产业与可持续消费博览会 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 10月16日至18日，2025可持续全球领导者大会在上海世博园区召开。粤开证券董事长郭川舟受邀出席大 会，并做主旨演讲。 他介绍，粤开证券背靠广州经开区——这一粤港澳大湾区内经济总量与科技创新水平均位居前列的核心 区域。基于此，公司在服务科技金融方面主要从三个层面展开，其中"转型"是首要任务。自2017年起， 集团及粤开证券在战略与主营业务上实现了全面转型。八年来，通过持续收购与整合，包括完成对粤开 证券的并购，公司构建了新的主营业务生态，目前旗下拥有三家上市公司，覆盖能源发电、生物医疗器 械及新能源板块，并成功发行了广东省首单产业园区REIT。集团亦是中国服务业企业500强及全国唯一 一家"双百企业"区属国企。 在服务科技产业的具体模式上，郭川舟指出是以"投资引领"为核心。他举例称，自并购粤开证券后，投 资板块持续聚焦"高精尖"领域，代表性项目包括投资了科创板生物医药市值领军企业百济神州，以及小 鹏汽车、文远知行等知名公司。持续的收并购不仅是资产提升、实现产业投资退出 ...

Core Insights - The Shanghai Stock Exchange Sci-Tech Innovation Board 100 Index has shown a slight increase of 0.21%, with notable gains from companies such as Sangfor Technologies and Dige Medical [3] - The ETF tracking the Sci-Tech 100 Index has also risen by 0.22%, with a cumulative increase of 1.81% for the month as of October 15, 2025 [3] - The liquidity of the Sci-Tech 100 Index ETF is strong, with a turnover rate of 1.93% and a transaction volume of 1.26 billion yuan [3] - Recent partnerships in the AI sector, such as the collaboration between Yuke and Haiguang Information, highlight the growing demand for AI computing power [4] - OpenAI's significant cloud computing contract with Oracle, valued at 300 billion USD, indicates a surge in global AI computing needs [4] Market Performance - The Sci-Tech 100 Index ETF has experienced a scale increase of 4.64 million yuan over the past month, ranking second among comparable funds [4] - The ETF's share count has grown by 2.76 million shares in the same period, also placing it second among comparable funds [4] - Despite recent net outflows of 1.56 million yuan, the ETF has attracted a total of 4.61 billion yuan over the last 16 trading days [4] Index Composition - The Sci-Tech 100 Index is composed of 100 medium-sized, liquid stocks selected from the Sci-Tech Innovation Board, reflecting the overall performance of different market capitalizations [5] - As of September 30, 2025, the top ten weighted stocks in the index account for 24.32% of the total index, including companies like Hua Hong Semiconductor and BeiGene [5]

Core Viewpoint - BeiGene's stock has shown significant volatility, with a year-to-date increase of 78.46%, but a recent decline over the past five and twenty trading days [1] Group 1: Stock Performance - As of October 16, BeiGene's stock price was 287.36 CNY per share, with a market capitalization of 442.73 billion CNY [1] - The stock experienced a 2.03% increase during the trading session on October 16, with a trading volume of 2.47 billion CNY and a turnover rate of 0.76% [1] - Year-to-date, the stock has risen by 78.46%, but it has decreased by 5.62% over the last five trading days and 9.35% over the last twenty trading days [1] Group 2: Financial Performance - For the first half of 2025, BeiGene reported a revenue of 17.518 billion CNY, representing a year-on-year growth of 46.03% [2] - The net profit attributable to shareholders for the same period was 450 million CNY, showing a significant increase of 115.63% year-on-year [2] Group 3: Shareholder Information - As of June 30, 2025, the number of BeiGene's shareholders was 23,300, a decrease of 3.90% from the previous period [2] - The average number of circulating shares per shareholder increased by 4.11% to 4,976 shares [2] - Among the top ten circulating shareholders, notable changes included an increase in holdings by China Europe Medical Health Mixed A and a decrease by Wan Jia You Xuan [2]

Group 1 - A-shares and Hong Kong stocks in the innovative pharmaceutical sector have rebounded, with significant gains in related stocks and ETFs [1][3][5] - The largest medical ETF in A-shares (512170) saw a trading volume of 589 million yuan, recovering 1.34% on the day [1] - The innovative drug sector is experiencing a collective rise, with notable stocks like Huahai Pharmaceutical increasing by 7.59% [3] Group 2 - The Hong Kong innovative drug ETF (520880) rose by 2.12%, with 35 out of 37 constituent stocks gaining, led by Green Leaf Pharmaceutical with an 8.31% increase [5][7] - Recent funding trends indicate a significant inflow into the innovative drug sector, with over 1.29 billion yuan added in the last three days [7] - Upcoming catalysts include the European Society for Medical Oncology (ESMO) annual meeting, which may showcase significant research results from Chinese innovative drugs [7] Group 3 - Investment strategies suggest focusing on innovative drugs, with specific ETFs like the Hong Kong innovative drug ETF (520880) and the A-share drug ETF (562050) highlighted for their potential [8] - The medical ETF (512170) is noted for its inclusion of CXO companies, which account for 26.77% of its weight [8] - The medical ETF is the largest in the market, with a scale of 26.4 billion yuan, while the drug ETF is the only one tracking the China Pharmaceutical Index [9]

Core Viewpoint - The innovative drug sector experienced a significant rally, with the innovative drug index rising by 2.35% as of the midday close on October 15, 2025, driven by strong performances from various companies [1][2]. Group 1: Market Performance - The innovative drug index (886015.TI) closed at 1366.835, reflecting a gain of 2.35%, equivalent to an increase of 31.422 points [2]. - Notable stock performances included Guangshentang, which surged by 20% to 122.65, and several other companies such as Shutaishen and Anglikang, which saw gains of 14.4% and 10.01%, respectively [2][3]. Group 2: Upcoming Events - The European Society for Medical Oncology (ESMO) conference is set to take place from October 17 to 21, 2025, in Berlin, Germany, where significant clinical research results and data are expected to be disclosed [3][4]. Group 3: Business Development Opportunities - There is growing market anticipation for the release of clinical data from domestic innovative drugs and business development (BD) collaborations, with 83 overseas BD transactions recorded in the first eight months of 2025, totaling 845 billion yuan, marking a 62.81% increase compared to the entire year of 2024 [4]. Group 4: Company Earnings Forecast - Several innovative drug companies are expected to report strong earnings for the third quarter of 2025, with Shengnuo Bio projecting a net profit of 114 million to 140 million yuan, representing a year-on-year increase of 100.53% to 145.10% [5]. - Boteng Co. anticipates a net profit of 73.2 million to 88.2 million yuan, indicating a turnaround from losses, driven by a 17% to 21% increase in revenue [5]. Group 5: Industry Outlook - Analysts express optimism regarding the innovative drug sector, anticipating stabilization and rebound due to upcoming catalysts such as BD and medical insurance negotiations [6]. - Long-term trends indicate that the Chinese pharmaceutical industry has transitioned to new growth drivers, particularly in innovative drugs, which are expected to significantly contribute to the growth of Chinese pharmaceutical companies over the next 5 to 10 years [7].

Core Insights - The Chinese biopharmaceutical industry is transitioning from traditional importation to independent innovation, with a projected increase in licensing-out transactions for innovative drugs reaching nearly $66 billion in the first half of 2025, surpassing the total of $51.9 billion for all of 2024 [1][2] - The rise of innovative drug development presents both opportunities and challenges for Chinese biopharmaceutical companies, with a need for enhanced capabilities in first-in-class drug development and global clinical research [2][3] Industry Trends - The trend towards global new drug development includes three main pathways: licensing projects to multinational companies, relying on contract R&D services, and fully independent global commercialization [2] - Despite advancements, first-in-class drugs remain scarce in China, indicating a need for increased investment in basic life sciences research [2][3] Data and Statistics - In the first half of 2023, overseas licensing amounts in China's pharmaceutical sector exceeded $60 billion, marking a significant shift from a generic drug powerhouse to a new drug exporter [2][3] - Shanghai leads the nation in licensing-out transactions, with 38 deals in 2024 amounting to $30.7 billion, representing 35% of the national total [3][5] Innovation and Collaboration - The integration of big data and artificial intelligence is transforming biopharmaceutical research, with high-quality data being crucial for accelerating new drug development [3][6] - Shanghai is fostering an innovative ecosystem that supports the entire chain from innovation to clinical transformation, with significant participation from top international pharmaceutical and medical device companies [5][6] Future Developments - Shanghai aims to enhance its role as a global biopharmaceutical innovation hub by promoting foundational research, clinical trials, and production processes [6]